BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:56 PM
 | 
Aug 30, 2007
 |  BC Extra  |  Clinical News

Rhucin meets HAE endpoint

Pharming (Euronext:PHARM) said interim data from 28 patients in a European Phase III trial to treat hereditary angioedema (HAE) showed that Rhucin recombinant human complement 1 esterase inhibitor ( rhC1INH) met the...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >